Q&A | Rise in tuberculosis cases result of more detection efforts, Nunavut CPHO says – Eye on the Arctic - Radio-Canada

NorthNunavut officials say the territory’s goal of eliminating tuberculosis by 2030 is still within reach, despite more cases this year than last.‘TB elimination by 2030 it is an ambitious goal, but it is also within our reach’CBC News · Posted: Oct 13, 2026 2:14 PM EDT | Last Updated: October 13Listen to this articleEstimated 8 minutesThe audio version of this article is generated by AI-based technology. Mispronunciations can occur. We are working with our partners to continually review and improve the results. Examining Nunavut's continuing fight against tuberculosisOctober 9|Duration 2:29Tuberculosis has played a huge role in the history of Nunavut. The disease has caused deaths, relocations and a lot of suffering. Though progress has been made to eradicate it, it's far from gone in the territory. Arty Sarkisian reports. Nunavut officials say the territory’s goal of eliminating tuberculosis by 2030 is still within reach, despite more cases this year than last. In an update in early October, the territory’s Department of Health reported 32 active cases of TB in the first three quarters of 2026 across seven communities.

Continuous glucose monitors (CGMs) could transform diabetes management for millions of Americans with type 2 diabetes who don't take insulin, according to findings published in the New England Journal of Medicine. The clinical trial found that adults using CGMs spent approximately five additional hours each day within their target blood sugar range compared with those receiving routine care. Nearly twice as many CGM users also achieved an A1c level below 7%, a common treatment goal for people with diabetes.

Patients who wore noise-canceling headphones during minimally invasive gynecological surgery were significantly less likely to experience postoperative nausea and vomiting (PONV), suggest findings from a randomized clinical trial presented at the Anesthesiology 2026 annual meeting.

“Beyond Detecting Cancer Recurrence: Can Whole-Genome Sequencing-Based ctDNA Monitoring Help Personalize Adjuvant Treatment? An exciting new study published in The Oncologist highlights the clinical potential of Signatera Genome, a whole-genome sequencing (WGS)-based, tumor-informed circulating tumor DNA (ctDNA) assay, not only for detecting molecular residual disease (MRD), but also for potentially informing adjuvant treatment decisions.